Chemoradiotherapy and gefitinib in stage III non-small cell lung cancer with epidermal growth factor receptor and KRAS mutation analysis: cancer and leukemia group B (CALEB) 30106, a CALGB-stratified phase II trial.

Chemoradiotherapy and gefitinib in stage III non-small cell lung cancer with epidermal growth factor receptor and KRAS mutation analysis: cancer and leukemia group B (CALEB) 30106, a CALGB-stratified phase II trial. J Thorac Oncol. 2010 Sep; 5(9):1382-90.

View in: PubMed

subject areas

Adenocarcinoma
Aged
Antineoplastic Combined Chemotherapy Protocols
Carboplatin
Carcinoma, Large Cell
Carcinoma, Non-Small-Cell Lung
Carcinoma, Squamous Cell
Combined Modality Therapy
Drug Resistance, Neoplasm
ErbB Receptors
Female
Humans
Lung Neoplasms
Male
Middle Aged
Mutation
Neoplasm Staging
Paclitaxel
Proto-Oncogene Proteins
Proto-Oncogene Proteins p21(ras)
Quinazolines
Radiotherapy
ras Proteins
Survival Rate
Treatment Outcome

authors with profiles

Everett E. Vokes